{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-126216","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.951021+00:00","generated_at":"2026-05-15T08:54:34.682866+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kyverna reports Q4/FY2025 results; cash $279M, SPS BLA on track for 1H 2026","bullets":["Net loss $37.8M Q4, $161.3M FY2025; R&D $30.0M Q4, G&A $9.3M Q4.","Cash and equivalents $279.3M; raised $147.5M in equity and $25M from loan facility.","SPS registrational trial met primary endpoints; BLA submission expected 1H 2026; launch-ready by YE 2026.","Phase 3 gMG trial enrolling; first patient Dec 2025; 14 sites active across three geographies.","Positive PMS Phase 1 data: 83% (5/6) patients achieved EDSS improvement; no high-grade CRS/ICANS."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-126216","json":"https://secwatch.observer/filing/0001193125-26-126216.json","markdown":"https://secwatch.observer/filing/0001193125-26-126216.md","text":"https://secwatch.observer/filing/0001193125-26-126216.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526126216/0001193125-26-126216-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526126216/kytx-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:54:34.682866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7089af0ef2d5098c97afb9c13156c42281938e2","claim":"Kyverna Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.","evidence_excerpt":"Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526126216/0001193125-26-126216-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}